STAT3 and lung cancer: In lung cancer 27, TSLNC8 overexpression led to smaller tumor volume and weight, reduced expression of EGFR, p-EGFR, and p-STAT3 levels, and combination with osimertinib administration effectively suppressed tumor growth, enhancing osimertinib's anti-tumor effects.